AOD9604

Apr 26, 2026 - 20:35

0 0

← Previous revision		Revision as of 15:04, 26 April 2026
Line 30:		Line 30:

	== Clinical data ==		== Clinical data ==
	In a 12 week [[randomised trial\|randomised clinical trial]], subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving [[placebo]].{{Cite journal \|last1=Valentino \|first1=Michael A. \|last2=Lin \|first2=Jieru E. \|last3=Waldman \|first3=Scott A. \|date=June 2010 \|title=Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy \|journal=Clinical Pharmacology and Therapeutics \|volume=87 \|issue=6 \|pages=652–662 \|doi=10.1038/clpt.2010.57 \|issn=0009-9236 \|pmc=3136748 \|pmid=20445536}} Development of AOD9604 was halted following ~~insignificant~~ efficacy in a later 24 week trial.		In a 12 week [[randomised trial\|randomised clinical trial]], subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving [[placebo]].{{Cite journal \|last1=Valentino \|first1=Michael A. \|last2=Lin \|first2=Jieru E. \|last3=Waldman \|first3=Scott A. \|date=June 2010 \|title=Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy \|journal=Clinical Pharmacology and Therapeutics \|volume=87 \|issue=6 \|pages=652–662 \|doi=10.1038/clpt.2010.57 \|issn=0009-9236 \|pmc=3136748 \|pmid=20445536}} Development of AOD9604 was halted following poor efficacy in a later 24 week trial.

	== References ==		== References ==